We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| Roche Holdings Ltd AG (QX) | USOTC:RHHBY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.07 | -0.23% | 29.75 | 29.55 | 30.50 | 30.05 | 29.53 | 29.80 | 5,444,214 | 21:57:01 |
From May 2022 to May 2024
By Cecilia Butini
Roche Holding AG said Wednesday that the European Commission has granted conditional marketing authorization for its cancer immunotherapy drug, Lunsumio, which was studied for use in patients with relapsed or refractory follicular lymphoma.
The Swiss pharma company said the drug is a new type of treatment which is chemotherapy-free and has a fixed duration. The treatment is off-the-shelf and readily available, which means that people don't have to wait to start treatment, the company said.
The European Union's approval is based on data from a Phase 1-2 trial. Conditional approval is granted to a drug that fulfils an unmet medical need, meaning the benefit of immediate availability outweighs the risk of having less comprehensive data, Roche said.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
June 08, 2022 01:34 ET (05:34 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Roche (QX) Chart |
1 Month Roche (QX) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
